https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39616 Dw,w), dose to water in medium (Dw,m), and dose to medium in medium (Dm,m). This was done based on a review of historical frameworks, existing literature and standards, clinical issues in the context of clinical trials, and the trajectory of radiation dose calculations. Based on these factors, recommendations were developed. Results: No framework was found to be ideal or perfect given the history, complexity, and current status of radiation therapy. Nevertheless, based on the evidence available, the GHG established a recommendation preferring dose to medium in medium (Dm,m). Conclusions: Dose to medium in medium (Dm,m) is the preferred dose calculation and reporting framework. If an institution’s planning system can only calculate dose to water in water (Dw,w), this is acceptable.]]> Wed 10 Aug 2022 11:54:01 AEST ]]> A virtual audit system for intensity-modulated radiation therapy credentialing in Japan Clinical Oncology Group clinical trials: A pilot study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51080 Fri 18 Aug 2023 09:31:34 AEST ]]>